LBA65 SAKK 08/14 - IMPROVE Investigation of metformin in patients with metastatic castration-resistant prostate cancer (mCRPC) in combination with enzalutamide vs. enzalutamide alone. A randomized, open label, phase II trial

Rothermundt, C.a.; Cathomas, R.; Gysel, K.; Fischer, N.; Mestre, R. Pereira; Hermanns, T.; Rothschild, S.i.; Mach, Nicolas; Mingrone, W.; Ciriolo, M.; Müller, B.; Erdmann, A.a.; Schär, C.; Mamot, C.; Bohanes, P.; Omlin, A.g.; Bastian, S.; Ribi, K.; Gillessen, S.

doi:10.1016/j.annonc.2022.08.068

Conference presentation

English

LBA65 SAKK 08/14 - IMPROVE Investigation of metformin in patients with metastatic castration-resistant prostate cancer (mCRPC) in combination with enzalutamide vs. enzalutamide alone. A randomized, open label, phase II trial

ContributorsRothermundt, C.a.; Cathomas, R.; Gysel, K.; Fischer, N.; Mestre, R. Pereira; Hermanns, T.; Rothschild, S.i.; Mach, Nicolas; Mingrone, W.; Ciriolo, M.; Müller, B.; Erdmann, A.a.; Schär, C.; Mamot, C.; Bohanes, P.; Omlin, A.g.; Bastian, S.; Ribi, K.; Gillessen, S.

Presented atESMO Congress 2022, Paris, 9-13 september 2022

Publication date2022-09

NotePublié dans : Annals of Oncology, 2022, 33(S7) : S1429

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

Immunothérapie (654)

Citation (ISO format)

ROTHERMUNDT, C.a. et al. LBA65 SAKK 08/14 - IMPROVE Investigation of metformin in patients with metastatic castration-resistant prostate cancer (mCRPC) in combination with enzalutamide vs. enzalutamide alone. A randomized, open label, phase II trial. In: ESMO Congress 2022. Paris. 2022. doi: 10.1016/j.annonc.2022.08.068

Presentation

OA OTHER

Identifiers

PID : unige:176125
DOI : 10.1016/j.annonc.2022.08.068

Additional URL for this publicationhttps://linkinghub.elsevier.com/retrieve/pii/S0923753422039461

53views

25downloads

Creation06/12/2023 13:37:51

First validation03/04/2024 07:48:31

Update time08/10/2024 15:14:40

Status update08/10/2024 15:14:40

Last indexation01/11/2024 09:07:13

Archive ouverte UNIGE

LBA65 SAKK 08/14 - IMPROVE Investigation of metformin in patients with metastatic castration-resistant prostate cancer (mCRPC) in combination with enzalutamide vs. enzalutamide alone. A randomized, open label, phase II trial

Technical informations